Abstract
Evasion from apoptotic cell death is reported to be a pivotal mechanism by which tumor cells acquire resistance to therapeutic treatment. Targeting the apoptotic pathways may constitute a promising strategy to counteract therapy resistance and to re-sensitize cancer cells. Expression of survivin, the smallest and structurally unique member of the inhibitor of apoptosis protein (IAP) family, has been shown to be associated with poor clinical outcome, more aggressive clinicopathologic features and resistance to both, conventional chemo and radiation therapy. Moreover, survivin detection in cancer tissue, in circulating tumor cells and in patient’s serum has prognostic and predictive relevance and may display a prerequisite for marker based molecular therapies. Indeed, due to its universal over expression in malignant tissue, and its prominent role at disparate networks of cellular division, intracellular signaling, apoptosis and adaption to unfavorable surroundings, survivin has been shown to be a suitable target for a targeted therapy. The applicability of survivindriven strategies in clinical practice is currently under investigation as the first survivin antagonists (small molecule inhibitors, antisense oligonucleotides and immunotherapy) successfully entered phase I/II trials. Taken together, these data provide a rationale for the implementation of both, survivin as a molecular diagnostic tool and survivin targeted therapies, within future clinical practice.
Keywords: IAP, Survivin, prognostic/predictive marker, cancer therapy
Current Medicinal Chemistry
Title:Survivin as a Prognostic/Predictive Marker and Molecular Target in Cancer Therapy
Volume: 19 Issue: 22
Author(s): F. Rodel, T. Sprenger, B. Kaina, T. Liersch, C. Rodel, S. Fulda and S. Hehlgans
Affiliation:
Keywords: IAP, Survivin, prognostic/predictive marker, cancer therapy
Abstract: Evasion from apoptotic cell death is reported to be a pivotal mechanism by which tumor cells acquire resistance to therapeutic treatment. Targeting the apoptotic pathways may constitute a promising strategy to counteract therapy resistance and to re-sensitize cancer cells. Expression of survivin, the smallest and structurally unique member of the inhibitor of apoptosis protein (IAP) family, has been shown to be associated with poor clinical outcome, more aggressive clinicopathologic features and resistance to both, conventional chemo and radiation therapy. Moreover, survivin detection in cancer tissue, in circulating tumor cells and in patient’s serum has prognostic and predictive relevance and may display a prerequisite for marker based molecular therapies. Indeed, due to its universal over expression in malignant tissue, and its prominent role at disparate networks of cellular division, intracellular signaling, apoptosis and adaption to unfavorable surroundings, survivin has been shown to be a suitable target for a targeted therapy. The applicability of survivindriven strategies in clinical practice is currently under investigation as the first survivin antagonists (small molecule inhibitors, antisense oligonucleotides and immunotherapy) successfully entered phase I/II trials. Taken together, these data provide a rationale for the implementation of both, survivin as a molecular diagnostic tool and survivin targeted therapies, within future clinical practice.
Export Options
About this article
Cite this article as:
Rodel F., Sprenger T., Kaina B., Liersch T., Rodel C., Fulda S. and Hehlgans S., Survivin as a Prognostic/Predictive Marker and Molecular Target in Cancer Therapy, Current Medicinal Chemistry 2012; 19 (22) . https://dx.doi.org/10.2174/092986712801661040
DOI https://dx.doi.org/10.2174/092986712801661040 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Advances in Synergistic Combinations of Chinese Herbal Medicine for the Treatment of Cancer
Current Cancer Drug Targets miRNA and Proteomic Dysregulation in Non-Small Cell Lung Cancer in Response to Cigarette Smoke
MicroRNA The Antibiotic Effects of Vitamin D
Endocrine, Metabolic & Immune Disorders - Drug Targets Biochemical Markers of Renal Function
Current Medicinal Chemistry Antihyperlipidemic and Antiobesity Potential of <i>Aquilaria agallocha</i> and <i>Borago officinalis</i> in Fixed-Dose Combination; A Contingent Probe with Atorvastatin and Orlistat
Current Bioactive Compounds Thermosensitive Polymeric Hydrogels As Drug Delivery Systems
Current Medicinal Chemistry Oncotarget Strategies For Herpes Simplex Virus-1
Current Gene Therapy Urine-derived Stem Cells, A New Source of Seed Cells for Tissue Engineering
Current Stem Cell Research & Therapy Exploring Quinolone Scaffold: Unravelling the Chemistry of Anticancer Drug Design
Mini-Reviews in Medicinal Chemistry Estrogen Receptor Signaling: Impact on Cell Functions
Current Signal Transduction Therapy Preparation and Primary Bioevaluation of 99mTc-labeled-1-thio-β-D-Glucose as Melanoma Targeting Agent
Current Radiopharmaceuticals New Perspectives in the Pharmacological Treatment of Non-Melanoma Skin Cancer
Current Drug Targets Novel Anticancer Agents and Targets: Recent Advances and Future Perspectives
Mini-Reviews in Medicinal Chemistry Targetin g Human Tel omerase by Antisens e Oligonucleotides and Ribozymes
Current Medicinal Chemistry - Anti-Cancer Agents Hyaluronan/Hyaladherins - a Promising Axis for Targeted Drug Delivery in Cancer
Current Drug Delivery Adaptor Protein 3BP2 and Cherubism
Current Medicinal Chemistry Use of Thiazolidinediones and Risk of Bladder Cancer: Disease or Drugs?
Current Drug Safety The Woman’s Heart: Insights into New Potential Targeted Therapy
Current Medicinal Chemistry Antiproliferative and Antifungal Activities of 1,3-diarylpropane-1,3-diones Commonly used as Sunscreen Agents
Letters in Drug Design & Discovery TNFα Modulation of Visceral and Spinal Sensory Processing
Current Pharmaceutical Design